Free Trial

iCAD Q2 2024 Earnings Report

iCAD logo
$1.83 +0.06 (+3.39%)
(As of 12/20/2024 05:16 PM ET)

iCAD Earnings Headlines

Missed Nvidia? Buy Elon Musk’s “Silent Partner”
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
US Penny Stocks To Watch In December 2024
See More iCAD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iCAD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iCAD and other key companies, straight to your email.

About iCAD

iCAD (NASDAQ:ICAD) engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

View iCAD Profile

More Earnings Resources from MarketBeat

Upcoming Earnings